Agent of saussurea ds plants possessing hepatoprotective action. RU patent 2464036.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to an agent possessing hepatoprotective activity and an ability to normalise the hepatic function. The use of a ground elevated part of Saussurea plants or an aqueous or aqueous-alcoholic or supercritical fluid extract of the elevated part of Saussurea plants as the agent possessing hepatoprotective activity and the ability to normalise the hepatic function.

EFFECT: agent possess manifested hepatoprotective activity and the ability to normalise the hepatic function.

3 cl, 1 tbl, 5 ex

IPC classes for russian patent Agent of saussurea ds plants possessing hepatoprotective action. RU patent 2464036. (RU 2464036):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K36/28 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

Another patents in same IPC classes:

Use of modified cyclosporines / 2463071
Group of inventions refers to medicine, particularly the use of non-immunosuppressive cyclophilin-binding cyclosporine for preventing or treating transplantation-related cirrhosis wherein cyclosporine (I) binds to human recombinant cyclophilin with a binding constant (BR) making less than 0.7 wherein BR represents a common logarithm of IC50 cyclosporine to IC50 cyclosporine A relation in concurrent experiment when evaluating by ELISA procedure; and (II) has activity in lymphocyte assay in the mixed culture making no more than 5% as compared with cyclosporine A activity (cl. 1) of the patent claim. There are also disclosed a pharmaceutical composition and a pharmaceutical combination containing cyclosporine under cl. 1.

Phospholipid nanoform for oral application (sachet) and method for preparing it (versions) / 2463057
Invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

Agent showing hepatoprotective action, and method for preparing it / 2462259
Invention refers to pharmaceutical industry, specifically to an agent showing hepatoprotective action. The agent showing hepatoprotective action of a herbal polyphenol extract of Amur maackia heartwood (Maxar) which represents an aqueous solution of Maxar in the molecular-capsulated form in the form of a water-soluble associated with a surfactant having a specific hydrophilic-lipophilic balance. A method for preparing the agent showing hepatoprotective action by Maxar homogenisation in the melt surfactant under certain conditions to produce the molecular-capsulated form of the end product.

Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy / 2462251
Invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.

Method of treating chronic viral hepatitis c / 2459629
Invention refers to medicine, namely hepatology and may be applicable in treating chronic viral hepatitis C. That is ensured by introducing short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil in the patient with an initial average week dosage specified in the range of 10.5 to 21.0 mil. IU depending on the level of native patient's interferon-alpha. Interferon-alpha is introduced with at least twice gradually increase of the average week dose to 21.0 to 84 mil. IU. Over the whole period of introducing IFN, the patient is prescribed with additional antiviral preparations - an interferon inducer, as well as an amantadin preparation or a glycyrrhizic acid preparation. It is combined with a support therapy involving the introduction of T-cell immunity stimulators and preparations for correction of side effects. The presence of blood viral ribonucleic acid is occasionally controlled and the introduction of Ribamidil is started in a daily dose of 800-1200 mg from the third month from the beginning of treatment if observing the presence of ribonucleic acid or from the tenth month if observing the absence. The treatment is continued until at least a 12-month aviremia period is achieved.

Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists

Method of prevention and treatment of liver disease with application of receptor a_2b antagonists / 2457842
Group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

Granule and method for making thereof / 2456980
Invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.

Method for preventing and treating hepatic consequences of ischemia / 2456678
Liver is resected in an animal experimentally. A pharmacological protection is presented by Mexicor and Serotonine Adipinate. On the operation day, 5% Mexicor is used in the form of intravenous slow stream introductions twice - 35 minutes before the operation in a dose of 5 mg/kg of weight and 11 hours after the first introduction in a dose of 7 mg/kg of weight. Serotonine Adipinate dissolved in 5 ml of isotonic solution NaCl is used in the form of intravenous slow stream introductions three times - 1 hour before the operation in a dose of 0.15 mg/kg of weight, 2 hours after the first introduction in a dose of 0.2 mg/kg of weight, 10 hours after the first introduction in a dose of 0.1 mg/kg of weight. During the postoperative period, Mexicor and Serotonine Adipinate are introduced for 8 days. Mexicor is introduced three times a day at 9 o'clock in a dose of 2.5 mg/kg of weight, at 15 o'clock in a dose of 1.5 mg/kg of weight, at 21 o'clock in a dose of 6 mg/kg of weight. Serotonine Adipinate is introduced twice a day - at 8 o'clock in a dose of 0.15 mg/kg of weight, at 17 o'clock in a dose of 0.1 mg/kg of weight.

Benzimidazole derivatives, based pharmaceutical composition and methods of using them / 2456276
Present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

Method of preventing liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process and means for its realisation / 2455988
Claimed is means for prevention (prophylaxis) of liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process, located outside the liver (CDDCMD in case of LCIP located outside the liver), which represents hormone of pineal gland - melatonin and corresponding method of prevention (prophylaxis) of liver injury in formation of CDDCMD in case of LCIP.

Method for preparing borneol from waste fir wood green extractives / 2464035
Invention refers to pharmaceutical and cosmetic industry, particularly to a method for preparing borneol. The method for preparing borneol from a hydrodistillate of a lipid portion of fir wood green extract involving saponification of the hydrodistillate in an alcohol solution of alkali, heating, stripping of alcohol and a portion of volatile ingredients, washing in hot still bottom water, separation of still bottom from an aqueous layer, crystallisation of borneol, filtration, washing in an organic solvent, re-crystallisation from mixed ethylacetate and petroleum benzene under certain conditions.

Method of treating tuberculosis complicated by intolerance to chemotherapy / 2464034
Invention refers to medicine, namely to phthisiology, and may be used for treating tuberculosis complicated by intolerance to chemotherapy. That is ensured by prescribing the product "Cedar Proteins" 15.0 g of powder dissolved in boiled water 150.0-200.0 ml once a day 1.5-2 h after breakfast for 21 days with underlying standard anti-tuberculosis chemotherapy.

Usnic acid and its oxidated derivative as influenza virus reproduction inhibitors / 2464033
Invention refers to pharmaceutics and concerns influenza virus reproduction inhibitors - the A/California/07/09 (H1N1)v strain representing (R)-usnic acid (1) and an oxidated derivative of (S)-usnic acid (2): .

Method for preparing shelf fungus extract / 2464032
Invention refers to pharmaceutical, food and cosmetic industry, particularly to a method for preparing a shelf fungus extract. The method for preparing a shelf fungus extract involving soaking of ground shelf fungus in an aqueous solution containing 5-15% dimethylsulphoxide and 2-8% sodium hydroxide under certain conditions, filtration and removal of the aqueous solution followed by staged extraction of the prepared raw material in water, filtration of the extract to provide a first degree of extraction and pulp to be extracted to provide a second degree of extraction, and merge of the extracts.

Hair conditioning composition / 2464012
Invention refers to cosmetology and concerns a hair conditioning composition containing: (a) 10 to 90 wt % of one or more ingredients specified in higher alcohols, higher fatty acids and their derivatives, (b) 5 to 35 wt % of a cationic surfactant, and (c) a polyatomic alcohol and/or polyethylene glycol having a melting point 155°C or less; wherein endothermic peak of the gel formed by the ingredients (a) and (b) in the composition makes 50°C or more as measured by a differential scanning calorimetre (DSC), the water content makes 10 wt % or less, and the molar ratio of the ingredient (a) to the ingredient (b) makes 2.5 to 6.0.

Cosmetic or pharmaceutical composition for local use / 2464011
Invention refers to chemical-pharmaceutical and cosmetic industry, and represents a cosmetic or pharmaceutical composition which contains a hydrophilic external phase, at least one cosmetic and/or pharmaceutical active ingredient, and at least one carrier for the active ingredient. The carrier forms such structures which contain at least two layers of plate-type double membrane sandwiched one above the other with a layer of an internal phase arranged between the adjoining parallel layers of the double membrane. The active ingredient is distributed in the layer of the double membrane and in the layer of the internal phase so that the layer of the internal phase contains the active ingredient within the range of concentrations 2 wt % to 98 wt %, and the layer of the double membrane contains the active ingredient within the range of concentrations 98 wt % to 2 wt % respectively in relation to the full concentration of the active ingredient, and the external phase does not contain or contains a very small amount of the active ingredient.

Method of treating patients with chronic lymphovenous insufficiency of lower extremities / 2464009
Invention refers to medicine, namely restorative medicine and angiology, and may be used for treating the patients with chronic lymphovenous insufficiency of lower extremities. That is ensured by applying a homogenised gel of brown algae at temperature 28-30°C and wrapping the extremities with non-woven tissues (drapes). That is followed by immediate alternative pneumatic compression by the Lympha-E apparatus on the lower extremities. That involves the ascending wave pressure memorising mode, the II operation mode at pressure 60-90 mm Hg for 40-60 minutes. The procedures are daily, 5 times a week with a pause of 2 days. The therapeutic course is 10-20 procedures.

Method of producing technetium-99m labelled nanocolloid / 2463075
Invention relates to a method of producing radioactive technetium-99m labelled nanocolloid. The method is characterised by adding a technetium-99m eluate to an aqueous suspension prepared from nanosized gamma-aluminium oxide powder with particle size of 7-10 nm and concentration of 0.5-0.7 mg/ml after bringing the pH of the medium to 4-5, followed by successive addition of ascorbic acid, tin (II) chloride dihydrate and gelatine in defined amounts. The obtained mixture is heated in a water bath at temperature 70-80°C for 30 minutes, cooled to room temperature in an ultrasonic bath and then subjected to sterilisation filtration.

Amino acid preparation eliciting antitumor effect and method for its preparing / 2245143
Invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.